[Form 4] BridgeBio Pharma, Inc. Insider Trading Activity

Rhea-AI Filing Summary

BridgeBio Pharma insider filing: Thomas Trimarchi, the company’s President and Chief Financial Officer, reported transactions in the issuer’s common stock. On 08/16/2025, 21,317 shares were withheld to satisfy tax withholding related to the vesting of 38,547 restricted stock units, leaving the reporting person with 480,671 shares beneficially owned. On 08/18/2025, Trimarchi sold a total of 17,353 shares under a Rule 10b5-1 sales plan adopted March 31, 2025, at weighted average prices of $50.1437 and $50.9439, reducing beneficial ownership to 463,318 shares. The Form 4 was signed by an attorney-in-fact on 08/19/2025.

Positive

• Transactions executed under a Rule 10b5-1 plan, indicating pre-planned and structured sales
• Tax withholding performed via share withholding for vested restricted stock units, a routine compensation settlement
• No derivative transactions reported in Table II, limiting complexity of insider exposure

Negative

• Officer sold 17,353 shares on 08/18/2025, reducing direct beneficial ownership
• 21,317 shares withheld on 08/16/2025 to satisfy tax obligations from RSU vesting

Insights

Corporate Governance Expert

TL;DR: Officer executed planned sales under a 10b5-1 plan and used RSU withholding for taxes, a routine insider liquidity event.

These transactions are consistent with a pre-established Rule 10b5-1 plan adopted March 31, 2025, which provides an affirmative defense to insider trading claims for scheduled sales. The withholding of 21,317 shares to cover taxes from vested RSUs reflects standard compensation tax settlement and does not create new equity issuance. Overall, the filing shows standard executive liquidity and tax withholding rather than ad hoc insider activity.

Securities Analyst

TL;DR: Officer reduced holdings by 17,353 shares via sales and 21,317 shares via tax withholding; total beneficial ownership declined to 463,318 shares.

The reporting person’s beneficial ownership decreased from 480,671 shares to 463,318 shares after the reported transactions. The sales occurred at weighted average prices noted in the filing ($50.14 and $50.94 ranges) and were effectuated under a 10b5-1 plan. For investors, this represents a modest reduction in insider holdings by a senior officer through pre-planned transactions and tax-related withholding.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Trimarchi Thomas

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CFO

3. Date of Earliest Transaction (Month/Day/Year)
08/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/16/2025		F		21,317(1)	D	$51.32	480,671	D
Common Stock	08/18/2025		S(2)		15,380	D	$50.1437(3)	465,291	D
Common Stock	08/18/2025		S(2)		1,973	D	$50.9439(4)	463,318	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 38,547 shares of Common Stock underlying the Reporting Person's Restricted Stock Units.

2. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

3. Represents the weighted average sale price of the shares sold from $49.76 to $50.75 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

4. Represents the weighted average sale price of the shares sold from $50.83 to $50.95 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

	/s/ Damian Wilmot, Attorney-in-Fact	08/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did BridgeBio (BBIO) insider Thomas Trimarchi report on the Form 4?

The Form 4 reports that Thomas Trimarchi had 21,317 shares withheld for taxes on 08/16/2025 and sold 17,353 shares on 08/18/2025 under a 10b5-1 plan.

How many shares does Trimarchi beneficially own after the reported transactions?

After the reported transactions, the filing shows 463,318 shares beneficially owned by the reporting person.

Were the sales discretionary or pre-planned for Trimarchi?

The sales were effected pursuant to a Rule 10b5-1 sales plan adopted March 31, 2025, per the filing.

What prices were the shares sold at according to the Form 4?

The filing reports weighted average sale price ranges: one set from $49.76 to $50.75 (weighted $50.1437) and another from $50.83 to $50.95 (weighted $50.9439).

Who signed the Form 4 and when was it signed?

The Form 4 was signed by Damian Wilmot, Attorney-in-Fact on 08/19/2025.